Company intelligence / Profile preview

Ingenics

Ownership: Private
Development stage: Other

Overview

Ingenix has developed a proprietary generative AI platform that simulates clinical trials using digital twins. The system integrates multimodal biological data—genomic, transcriptomic, proteomic, imaging, and phenotypic—to model processes from molecular to population levels. It predicts clinical endpoints and adverse events with high granularity to support preclinical candidate selection and optimize R&D investments. The company recently raised €9 million in seed funding to expand its team and scale its infrastructure

Industry: Drug Discovery Services

Beyond the preview

Go deeper on Ingenics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ingenics.

Explore the full profile